• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Research Brief on Ethyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS: 1198615-87-0) in Chemical Biology and Pharmaceutical Applications

Ethyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS: 1198615-87-0) is a boronic ester derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of bioactive molecules, particularly in the development of boron-containing drugs, which are increasingly recognized for their therapeutic potential. The unique properties of the boronate moiety, including its ability to form reversible covalent bonds with diols and its role in Suzuki-Miyaura cross-coupling reactions, make this compound a valuable tool in medicinal chemistry and drug discovery.

Recent studies have highlighted the role of Ethyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the synthesis of proteasome inhibitors and other targeted therapies. For instance, researchers have utilized this compound to develop novel boron-based inhibitors that selectively target cancer cell pathways. The boronic acid functional group, when incorporated into drug candidates, can enhance binding affinity and specificity, leading to improved therapeutic outcomes. Additionally, its stability under physiological conditions makes it an attractive candidate for further pharmaceutical development.

In the context of chemical biology, this compound has been employed as a building block for the design of molecular probes and sensors. Its ability to interact with biological macromolecules, such as proteins and nucleic acids, has enabled researchers to study complex cellular processes with high precision. Recent advancements in biorthogonal chemistry have further expanded its utility, allowing for the selective labeling and tracking of biomolecules in live cells. These applications underscore the compound's potential in both basic research and translational medicine.

From a synthetic perspective, Ethyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is often synthesized via palladium-catalyzed borylation reactions, which offer high yields and excellent regioselectivity. Recent methodological improvements have focused on optimizing reaction conditions to reduce byproduct formation and enhance scalability. These advancements are critical for the large-scale production of boron-containing pharmaceuticals, where purity and efficiency are paramount.

Looking ahead, the continued exploration of Ethyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and related boronic esters is expected to yield new insights into their therapeutic mechanisms and applications. Ongoing research is investigating their potential in treating neurodegenerative diseases, infectious diseases, and inflammatory disorders. Furthermore, the integration of computational modeling and high-throughput screening techniques is accelerating the discovery of novel boron-based drug candidates, positioning this compound as a cornerstone of future pharmaceutical innovation.

• 269409-99-6(Ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 891843-56-4(Benzoic acid, 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-,methyl ester)
• 849677-21-0(5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2-benzofuran-1,3-dione)
• 525362-07-6(methyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 1245617-64-4(Ethyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 955929-54-1(Methyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 1073493-92-1(4-(t-Butoxycarbonyl)-2-methylphenylboronic Acid Pinacol Ester)
• 882679-40-5(Methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)benzoate)
• 1080573-22-3(Methyl 4-(acetoxymethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 478375-39-2(Methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)